[go: up one dir, main page]

WO2007142929A3 - Novel pde4 inhibitors - Google Patents

Novel pde4 inhibitors Download PDF

Info

Publication number
WO2007142929A3
WO2007142929A3 PCT/US2007/012668 US2007012668W WO2007142929A3 WO 2007142929 A3 WO2007142929 A3 WO 2007142929A3 US 2007012668 W US2007012668 W US 2007012668W WO 2007142929 A3 WO2007142929 A3 WO 2007142929A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
pde4 inhibitors
compounds
disorders
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/012668
Other languages
French (fr)
Other versions
WO2007142929A2 (en
Inventor
Ke Hengming
Gurpreet Kaur
Binghe Wang
Shi-Long Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Georgia State University Research Foundation Inc
Original Assignee
University of North Carolina at Chapel Hill
Georgia State University Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, Georgia State University Research Foundation Inc filed Critical University of North Carolina at Chapel Hill
Publication of WO2007142929A2 publication Critical patent/WO2007142929A2/en
Publication of WO2007142929A3 publication Critical patent/WO2007142929A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PDE4 inhibitors, pharmaceutical compositions including the inhibitors, and methods of treatment using the inhibitors are disclosed. The compounds are illustrated by Formulas 1-9 in the specification. The compounds can be used to treat a variety of disorders mediated by phosphodiesterase, and TNF-α, including asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, central nervous system disorders, cardiovascular disorders, and tumor progression.
PCT/US2007/012668 2006-05-31 2007-05-29 Novel pde4 inhibitors Ceased WO2007142929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80975106P 2006-05-31 2006-05-31
US60/809,751 2006-05-31

Publications (2)

Publication Number Publication Date
WO2007142929A2 WO2007142929A2 (en) 2007-12-13
WO2007142929A3 true WO2007142929A3 (en) 2008-04-24

Family

ID=38801992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/012668 Ceased WO2007142929A2 (en) 2006-05-31 2007-05-29 Novel pde4 inhibitors

Country Status (2)

Country Link
CN (1) CN101495454A (en)
WO (1) WO2007142929A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013155123A1 (en) 2012-04-10 2013-10-17 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN107714686B (en) * 2016-08-10 2020-01-14 广州华真医药科技有限公司 Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of drugs for treating prostatic cancer hyperplasia and metastasis
JP7362596B2 (en) 2017-06-12 2023-10-17 オブシディアン セラピューティクス， インコーポレイテッド PDE5 compositions and methods for immunotherapy
WO2018237323A1 (en) * 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University DOMAINS OF DETABILIZATION OF PDE5A
CN112996492A (en) * 2018-09-05 2021-06-18 阿姆斯特丹大学 Use of PDE11 or PDE2 inhibitors for the treatment of Parkinson's disease
CN109908139B (en) * 2018-12-28 2022-02-22 南京市儿童医院 Use of cilomilast for the preparation of a medicament for the treatment of a disorder associated with acute kidney injury
CN110003102B (en) * 2019-05-16 2022-03-22 河南师范大学 (R) -2- (alpha-deuterium-alpha-alkyl-alpha-aromatic) nitrogen heteroaryl compound and preparation method and application thereof
CN110279686A (en) * 2019-08-01 2019-09-27 汪海涛 A kind of phosphodiesterase 4 inhibitors are preventing and are treating the application in Parkinson's disease
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
ES2989065T3 (en) * 2020-05-28 2024-11-25 Giiant Pharma Inc Bioactivated PDE4 inhibitor precursors from the intestinal microbiota
WO2022056265A1 (en) * 2020-09-10 2022-03-17 Vanda Pharmaceuticals Inc. Methods of treating pde iv-mediated diseases or conditions
CN118994068A (en) * 2023-05-19 2024-11-22 上海中医药大学 Phosphodiesterase 4 inhibitor, pharmaceutical composition and application thereof
CN117924243B (en) * 2024-01-16 2025-09-12 沈阳药科大学 A quinoline derivative and its pharmaceutical composition and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838930A (en) * 1985-04-01 1989-06-13 Ciba-Geigy Corporation 3-fuoropyridyl-2-oxy-phenoxy derivatives having herbicidal activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838930A (en) * 1985-04-01 1989-06-13 Ciba-Geigy Corporation 3-fuoropyridyl-2-oxy-phenoxy derivatives having herbicidal activity

Also Published As

Publication number Publication date
CN101495454A (en) 2009-07-29
WO2007142929A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2007142929A3 (en) Novel pde4 inhibitors
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2007084557A3 (en) Azaindoles useful as inhibitors of janus kinases
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2008137619A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
NO20090268L (en) Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
WO2008005303A3 (en) Thiazolopyrimidine modulators of trpv1
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
WO2007114848A3 (en) Chemical compounds
NO20070319L (en) Novel pyridazine-3 (2H) -one derivatives and their use as PDE4 inhibitors
WO2008079521A3 (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
MX2009010270A (en) Indole carboxamides as ikk2 inhibitors.
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
NO341676B1 (en) Tetrahydro-pyrimidoazepines as modulators of TRPVI
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
WO2008144720A3 (en) Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2007071313A3 (en) Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028662.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07795453

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07795453

Country of ref document: EP

Kind code of ref document: A2